Ninth protocol extends range of therapeutic apheresis and cell collection procedures available on a single device
LAKEWOOD, Colo.—April 4, 2013—Bone Marrow Processing (BMP), the ninth protocol on the Terumo BCT Spectra Optia system, has been released for use in Europe and Australia. With this release, the number of protocols available on the Spectra Optia system in Europe, the Middle East and Africa (EMEA) is equal to those on the predecessor device, the COBE® Spectra Apheresis System.
The Spectra Optia system enables facilities to perform nine procedures, including one processing protocol, four exchange protocols, two depletion protocols and two collection protocols
The Spectra Optia system performs BMP procedures in less than 90 minutes with a high degree of precision:
Red cell reduction greater than 97 percent
Volume reduction greater than 80 percent
Final product volume less than 200 mL
- The Spectra Optia system offers therapeutic plasma exchange (TPE) and mononuclear cell (MNC) collection protocols in the U.S.
The Spectra Optia system is the industry's next-generation therapeutic apheresis and cell collection platform that allows operators to spend more time focusing on patient care. From therapeutic apheresis to cell collection, the Spectra Optia system provides facilities with the versatility to perform a range of procedures with on-screen instructions to guide operators through setup, monitoring and adjustments.
Bob Sullivan, Terumo BCT, Vice President of Therapeutic Systems Worldwide Sales and Marketing
"The release of BMP marks an ideal time for our customers to convert from the COBE Spectra system to the advanced Spectra Optia system. With the Spectra Optia system, clinical facilities have more versatility in treating patients and tailoring treatments to their individual needs."
About Terumo BCT:
Terumo BCT, a global leader in blood component, therapeutic apheresis and cellular technologies, is the only company with the unique combination of apheresis collections, manual and automated whole blood processing, and pathogen reduction coupled with leading technologies in therapeutic apheresis and cell processing. We believe in the potential of blood to do even more for patients than it does today. This belief inspires our innovation and strengthens our collaboration with customers.